IRIS
MENNA, PIERANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.305
NA - Nord America 755
EU - Europa 399
SA - Sud America 86
AF - Africa 18
OC - Oceania 13
Totale 5.576
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.369
US - Stati Uniti d'America 705
CN - Cina 506
HK - Hong Kong 297
GB - Regno Unito 102
DE - Germania 79
BR - Brasile 67
IT - Italia 59
CZ - Repubblica Ceca 54
VN - Vietnam 47
FI - Finlandia 25
IN - India 25
CA - Canada 23
MX - Messico 21
NL - Olanda 18
AU - Australia 12
ZA - Sudafrica 11
ID - Indonesia 10
PL - Polonia 9
AR - Argentina 8
BD - Bangladesh 8
JP - Giappone 8
FR - Francia 7
UA - Ucraina 7
BE - Belgio 6
PK - Pakistan 6
ES - Italia 5
TR - Turchia 5
PT - Portogallo 4
TW - Taiwan 4
AL - Albania 3
AT - Austria 3
CL - Cile 3
EE - Estonia 3
LT - Lituania 3
PY - Paraguay 3
SE - Svezia 3
AE - Emirati Arabi Uniti 2
CO - Colombia 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
GE - Georgia 2
IE - Irlanda 2
IQ - Iraq 2
MY - Malesia 2
PH - Filippine 2
RU - Federazione Russa 2
TN - Tunisia 2
UZ - Uzbekistan 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
CR - Costa Rica 1
CV - Capo Verde 1
DK - Danimarca 1
DM - Dominica 1
GA - Gabon 1
IL - Israele 1
JO - Giordania 1
KN - Saint Kitts e Nevis 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MR - Mauritania 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
RO - Romania 1
SA - Arabia Saudita 1
VE - Venezuela 1
YE - Yemen 1
Totale 5.576
Salva come PNG Salva come JPEG
Città #
Singapore 313
Hong Kong 295
Hefei 183
Ashburn 175
Beijing 111
Boardman 106
London 82
Dallas 63
Shanghai 59
Munich 48
Brno 35
Los Angeles 34
Rome 30
Council Bluffs 29
San Francisco 26
Redmond 20
Pune 18
Amsterdam 17
Ho Chi Minh City 17
Mexico City 17
Olomouc 17
Turku 14
Seattle 13
São Paulo 12
Guangzhou 11
Hanoi 11
Helsinki 11
Santa Clara 11
Washington 11
New York 10
Toronto 10
Boston 9
Manchester 8
Brooklyn 7
Tokyo 7
Warsaw 7
Melbourne 6
Chicago 5
Atlanta 4
Haikou 4
Haiphong 4
Johannesburg 4
Montreal 4
Ankara 3
Biên Hòa 3
Campinas 3
Canberra 3
Chennai 3
Dhaka 3
Hangzhou 3
Hanover 3
Karachi 3
Mol 3
Oklahoma City 3
Paris 3
Stockholm 3
Sydney 3
Taipei 3
Tirana 3
Wuhan 3
Aversa 2
Bismarck 2
Buenos Aires 2
Colombo 2
Concord 2
Curitiba 2
Dublin 2
Florence 2
Genoa 2
Grand Rapids 2
Hasselt 2
Iowa City 2
Kuala Lumpur 2
Lodz 2
Luoyang 2
Madrid 2
New Delhi 2
North Liberty 2
Nuremberg 2
Palermo 2
Phoenix 2
Porto 2
Quito 2
Rio de Janeiro 2
Shanwei 2
Shenzhen 2
Tallinn 2
Tashkent 2
Tbilisi 2
The Dalles 2
Thái Nguyên 2
Topeka 2
Vilnius 2
West Jordan 2
Xi'an 2
Xiamen 2
Zhengzhou 2
Alcobaça 1
Alfenas 1
Almaty 1
Totale 2.006
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 205
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 188
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 188
Cancer drugs and QT prolongation: weighing risk against benefit 185
Minimal sampling colistin pharmacokinetics in critically ill patients 185
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 179
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 179
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 175
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 172
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 171
Cardio-oncology in clinical studies and real life 170
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 162
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 155
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 139
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 127
Anthracyclines 109
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 108
Anthracycline Cardiotoxicity 107
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 101
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 100
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 98
Anthracycline Cardiotoxicity 91
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 87
An introduction to the metabolic determinants of anthracycline cardiotoxicity 81
Cardiotoxicity of antitumor drugs 76
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 71
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 70
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 69
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 55
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 53
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 53
Pharmacology of Cardio-Oncology 48
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 47
What is cardiotoxicity? 45
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 44
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 42
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 39
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 38
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 38
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 37
Isavuconazole: case report and pharmacokinetic considerations 37
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 37
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 36
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 36
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 36
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 35
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 35
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 35
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 35
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 33
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 32
Matters of the heart: The case of TNF-alpha targeting drugs 32
The concomitant management of cancer therapy and cardiac therapy 31
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 30
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 29
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 28
Pharmacological Foundation of Cardio-Oncology 28
Molecular determinants of the reduced cardiotoxicity of epirubicin 28
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 27
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 27
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 27
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 27
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 26
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 26
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 26
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 26
Doxorubicin degradation in cardiomyocytes 25
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 25
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 25
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 25
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 24
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 24
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 24
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 23
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 22
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 22
In ®Entresto we trust 22
Translating molecular mechanisms into clinical facts 22
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 22
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 22
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 22
Humans and Rodents: The Case of hOAT4 and mOat5 21
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs/Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici 21
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 21
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 20
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 19
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 19
Do you know pixantrone? 18
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 18
The reality of pixantrone in real life 17
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 17
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 16
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 16
Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study 13
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 3
Totale 5.680
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.864
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.864
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 4 0 0 0 0 1 92 4 0 5 112
2022/202356 2 1 1 4 2 2 15 0 3 3 22 1
2023/2024333 6 35 11 15 37 146 1 16 2 8 4 52
2024/20254.043 102 36 123 15 45 77 40 21 250 263 1.446 1.625
2025/20261.030 336 204 131 250 109 0 0 0 0 0 0 0
Totale 5.680